Summit Therapeutics PLC Sponsored ADR Stock

$19.19

1.00% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Summit Therapeutics PLC Sponsored ADR Stock price

$19.19

+17.65 1,146.10% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

+0.19 1.00%

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$14.14b
Enterprise Value	$13.69b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	32.30
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-181.89m
Free Cash Flow (TTM) Free Cash Flow	$-113.54m
Cash position	$487.22m
EPS (TTM) EPS	$-0.28
P/E forward	negative
Short interest	14.34%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

3x Buy

75%

1x Hold

25%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy

75%

Hold

25%

Analyst Estimates with Stock Price Targets

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.67 0.67	67% 67% -
Gross Profit	-0.67 -0.67	67% 67% -
- Selling and Administrative Expenses	56 56	152% 152% -
- Research and Development Expense	124 124	212% 212% -
EBITDA	-181 -181	182% 182% -
- Depreciation and Amortization	0.67 0.67	67% 67% -
EBIT (Operating Income) EBIT	-182 -182	174% 174% -
Net Profit	-197 -197	67% 67% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Summit Therapeutics PLC Sponsored ADR Stock News

Positive

The Motley Fool

●

3 days ago

3 Monster Stocks in the Making

Neutral

Business Wire

●

5 days ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 227,600 shares of common stock. Awards were made to 15 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company ...

Neutral

Investors Business Daily

●

12 days ago

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug. The post Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics appeared first on Investor's Business Daily.

More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office	United Kingdom
CEO	Robert Zanganeh
Employees	105
Founded	2003
Website	www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now